Recent News

• 02.25.2026 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 02.24.2026 - Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
• 02.23.2026 - Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• 02.18.2026 - Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 02.17.2026 - Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
• 01.27.2026 - Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

Recent Filings

• 02.26.2026 - 144 Report of proposed sale of securities
• 02.26.2026 - 144 Report of proposed sale of securities
• 02.25.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.23.2026 - 8-K Current report
• 02.23.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.23.2026 - EX-99.1 EX-99.1
• 02.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - EX-99.1 EX-99.1
• 02.17.2026 - 8-K Current report
• 02.10.2026 - 4 Statement of changes in beneficial ownership of securities